UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,880 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 6.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 66,078 shares of the biotechnology company’s stock after selling 4,880 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.13% of REGENXBIO worth $693,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in shares of REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 17,533 shares during the period. FMR LLC lifted its holdings in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock valued at $4,382,000 after purchasing an additional 37,055 shares during the last quarter. Intech Investment Management LLC bought a new position in REGENXBIO during the third quarter worth about $161,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of REGENXBIO in the third quarter worth about $643,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now directly owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. The trade was a 46.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 13.13% of the stock is owned by company insiders.

REGENXBIO Stock Down 4.6 %

NASDAQ:RGNX opened at $7.41 on Friday. The stock has a market cap of $367.13 million, a P/E ratio of -1.47 and a beta of 1.24. The business’s 50-day moving average price is $9.67 and its two-hundred day moving average price is $11.27. REGENXBIO Inc. has a twelve month low of $7.38 and a twelve month high of $28.80.

Analyst Upgrades and Downgrades

RGNX has been the topic of a number of recent research reports. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Raymond James restated an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Wednesday, November 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $35.00 price objective on shares of REGENXBIO in a research note on Wednesday, December 11th. Finally, Morgan Stanley reissued an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $35.27.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.